A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Metformin Compared to Metformin Plus Placebo in Subjects in Russia With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 May 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms IMPRESSION
- Sponsors Astellas Pharma Europe Ltd
- 07 Jun 2017 Biomarkers information updated
- 19 May 2017 Planned primary completion date changed from 1 Feb 2017 to 25 May 2017.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.